title: High-dose-rate intraluminal brachytherapy for bile duct carcinoma after surgery.
abstract: Five patients with recurrent or residual bile duct carcinoma after surgery were treated with high-dose-rate intraluminal brachytherapy (HDRIBT) using a remote afterloader. External radiotherapy was also given in three cases. HDRIBT is considered to be an effective mode of radiotherapy for residual or recurrent bile duct tumors.
authors.affiliation: Department of Radiology, Hyogo College of Medicine, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Kurisu
authors.forename: Y
authors.initials: Y
authors.lastname: Hishikawa
authors.forename: M
authors.initials: M
authors.lastname: Taniguchi
authors.forename: N
authors.initials: N
authors.lastname: Kamikonya
authors.forename: T
authors.initials: T
authors.lastname: Miura
authors.forename: H
authors.initials: H
authors.lastname: Kanno
authors.forename: E
authors.initials: E
authors.lastname: Okamoto
mesh_terms: D001650:Bile Duct Neoplasms / Q000532:radiotherapy / Q000601:surgery*; D001918:Brachytherapy; D002763:Cholecystectomy; D003131:Combined Modality Therapy; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control / Q000532:radiotherapy; D010166:Palliative Care; D011182:Postoperative Care; D011882:Radiotherapy, High-Energy